Signet Healthcare Partners Facilitates Paragonix Acquisition
Signet Healthcare Partners is excited to share a significant advancement in medical technology: Getinge has acquired Paragonix Technologies. Known for its cutting-edge solutions in organ transplantation and preservation, Paragonix is set for remarkable growth as a result of this acquisition.
Signet's Investment Role in Paragonix
The relationship between Signet and Paragonix began in 2023 when Signet led a $25 million Series B investment. This strategic funding was pivotal in accelerating Paragonix’s mission to elevate care standards in organ transplantation. Being the first institutional investor, Signet played a key role in driving Paragonix's growth, culminating in an acquisition that expanded the company's service offerings.
Leadership and Growth at Paragonix
Thanks to the leadership of Dr. Lisa Anderson, Paragonix has experienced remarkable organic growth, enhancing its market presence across the globe. The company's innovative devices for cardiothoracic and abdominal transplantation have quickly gained acclaim, setting new benchmarks for safety and efficiency in the transplant process.
Acknowledgements from Leadership
Ashley Friedman, Managing Director at Signet and a Board Director at Paragonix, shared her pride in the collaborative efforts between the two organizations. She praised Dr. Anderson and her team for their dedication to advancing transplantation technology. Ashley stressed that with Getinge’s extensive resources, Paragonix is well-equipped to continue innovating and improving patient care outcomes.
The Impact of the Acquisition
Dr. Anderson commented on the essential support provided by Signet Healthcare Partners throughout this journey, highlighting the invaluable commercial scaling expertise they brought. This collaboration has set Paragonix up for a successful acquisition, creating a leading platform within the organ transplantation sphere. The partnership with Getinge is anticipated to enhance their worldwide influence and further develop their technology.
Signet's Investment Fund V
Paragonix is among the first three investments from Signet’s new venture, Signet Healthcare Partners Fund V, which targets commercial-stage pharmaceutical and medical device firms. Typically, the fund invests around $20 million per opportunity, underscoring Signet’s commitment to fostering advancements in innovative healthcare initiatives.
About Signet Healthcare Partners
Signet Healthcare Partners is recognized for its role in providing growth capital to top healthcare companies, particularly in the pharmaceutical and medical device sectors. With an impressive track record spanning over 25 years, Signet has raised upwards of $600 million and invested in more than 60 businesses. Their proactive approach helps portfolio companies achieve substantial growth.
About Paragonix Technologies
Paragonix Technologies is leading the way in the organ transplant sector, developing Advanced Organ Preservation (AOP) devices that ensure the safe transportation of donor organs. These FDA-cleared and CE-marked devices utilize reliable preservation techniques that maintain both physical and thermal safety during transit. Each AOP device comes with a unique digital app, enabling real-time tracking for transplant teams, which streamlines operations.
Frequently Asked Questions
What was the significance of Signet's investment in Paragonix?
Signet's investment provided crucial capital and strategic guidance to help Paragonix expand its innovative organ transplantation solutions.
How does the acquisition by Getinge benefit Paragonix?
Getinge's global reach and resources will enhance Paragonix’s ability to innovate and improve patient care in organ transplantation.
What technologies does Paragonix specialize in?
Paragonix specializes in Advanced Organ Preservation devices that safeguard donor organs during transportation, enhancing the transplantation process.
What is Signet's approach to investment?
Signet focuses on growth capital investments in healthcare, supporting innovative companies in achieving their growth potential through active involvement.
How long has Signet been in the healthcare investment sector?
Signet has over 25 years of experience in the healthcare investment sector, with a portfolio that includes more than 60 companies.
